N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
View ORCID ProfileSevastyan O. Rabdano, View ORCID ProfileEllina A. Ruzanova, Anastasiya E. Vertyachikh, Valeriya A. Teplykh, Alla B. Emelyanova, View ORCID ProfileGerman O. Rudakov, View ORCID ProfileSergei A. Arakelov, View ORCID ProfileIuliia V. Pletyukhina, View ORCID ProfileNikita S. Saveliev, Anna A. Lukovenko, View ORCID ProfileLiliya N. Fakhretdinova, View ORCID ProfileAriana S. Safi, Ekaterina N. Zhirenkina, Irina N. Polyakova, View ORCID ProfileNatalia S. Belozerova, Vladislav V. Klykov, Arina P. Savelieva, Aleksey A. Ekimov, View ORCID ProfileVadim A. Merkulov, View ORCID ProfileSergei M. Yudin, View ORCID ProfileDaria S. Kruchko, View ORCID ProfileIgor A. Berzin, Veronika I. Skvortsova, Clinical Trial Group
doi: https://doi.org/10.1101/2024.04.01.24304717
Sevastyan O. Rabdano
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Ellina A. Ruzanova
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Anastasiya E. Vertyachikh
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Valeriya A. Teplykh
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Alla B. Emelyanova
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
German O. Rudakov
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Sergei A. Arakelov
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Iuliia V. Pletyukhina
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Nikita S. Saveliev
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Anna A. Lukovenko
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Liliya N. Fakhretdinova
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Ariana S. Safi
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Ekaterina N. Zhirenkina
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Irina N. Polyakova
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Natalia S. Belozerova
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Vladislav V. Klykov
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Arina P. Savelieva
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Aleksey A. Ekimov
1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
Vadim A. Merkulov
2I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
3Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, Moscow, Russia
Sergei M. Yudin
4Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological Agency, Moscow, Russia
Daria S. Kruchko
5Federal Medical-Biological Agency of Russia, Moscow, Russia
Igor A. Berzin
5Federal Medical-Biological Agency of Russia, Moscow, Russia
Veronika I. Skvortsova
5Federal Medical-Biological Agency of Russia, Moscow, Russia
- Clinical Trial Group[supplements/304717_file03.pdf]
Posted April 09, 2024.
N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina A. Ruzanova, Anastasiya E. Vertyachikh, Valeriya A. Teplykh, Alla B. Emelyanova, German O. Rudakov, Sergei A. Arakelov, Iuliia V. Pletyukhina, Nikita S. Saveliev, Anna A. Lukovenko, Liliya N. Fakhretdinova, Ariana S. Safi, Ekaterina N. Zhirenkina, Irina N. Polyakova, Natalia S. Belozerova, Vladislav V. Klykov, Arina P. Savelieva, Aleksey A. Ekimov, Vadim A. Merkulov, Sergei M. Yudin, Daria S. Kruchko, Igor A. Berzin, Veronika I. Skvortsova, Clinical Trial Group
medRxiv 2024.04.01.24304717; doi: https://doi.org/10.1101/2024.04.01.24304717
N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina A. Ruzanova, Anastasiya E. Vertyachikh, Valeriya A. Teplykh, Alla B. Emelyanova, German O. Rudakov, Sergei A. Arakelov, Iuliia V. Pletyukhina, Nikita S. Saveliev, Anna A. Lukovenko, Liliya N. Fakhretdinova, Ariana S. Safi, Ekaterina N. Zhirenkina, Irina N. Polyakova, Natalia S. Belozerova, Vladislav V. Klykov, Arina P. Savelieva, Aleksey A. Ekimov, Vadim A. Merkulov, Sergei M. Yudin, Daria S. Kruchko, Igor A. Berzin, Veronika I. Skvortsova, Clinical Trial Group
medRxiv 2024.04.01.24304717; doi: https://doi.org/10.1101/2024.04.01.24304717
Subject Area
Subject Areas
- Addiction Medicine (380)
- Allergy and Immunology (697)
- Anesthesia (187)
- Cardiovascular Medicine (2817)
- Dermatology (241)
- Emergency Medicine (425)
- Epidemiology (12511)
- Forensic Medicine (10)
- Gastroenterology (797)
- Genetic and Genomic Medicine (4380)
- Geriatric Medicine (398)
- Health Economics (711)
- Health Informatics (2824)
- Health Policy (1042)
- Hematology (372)
- HIV/AIDS (892)
- Medical Education (412)
- Medical Ethics (113)
- Nephrology (460)
- Neurology (4144)
- Nursing (219)
- Nutrition (614)
- Oncology (2182)
- Ophthalmology (620)
- Orthopedics (253)
- Otolaryngology (316)
- Pain Medicine (262)
- Palliative Medicine (81)
- Pathology (483)
- Pediatrics (1166)
- Primary Care Research (481)
- Public and Global Health (6727)
- Radiology and Imaging (1479)
- Respiratory Medicine (895)
- Rheumatology (429)
- Sports Medicine (359)
- Surgery (468)
- Toxicology (57)
- Transplantation (198)
- Urology (173)